Metraipolis › archive › dc_489d49160e68

Safety profile and efficacy of secukinumab in the treatment of autoimmune myasthenia gravis: a single-center retrospective study — Europe PMC PMID:41200446

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41200446
DOI
10.3389/fneur.2025.1642938
License (as archived)
solo-consultazione
Archived
2026-11-09T03:56:08.373Z
SHA-256 of the archived text
9b03356b2030c7e68f4fe7f23de7b044b7c29899a8a6df09cd7c5228bf8a0482
Stable URL of this page
https://metraipolis.com/documento/dc_489d49160e68

How to cite

Safety profile and efficacy of secukinumab in the treatment of autoimmune myasthenia gravis: a single-center retrospective study — Europe PMC PMID:41200446 — Europe PMC (en), https://europepmc.org/article/MED/41200446 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_489d49160e68 (Metraipolis archive dc_489d49160e68, sha256 9b03356b2030c7e68f4fe7f23de7b044b7c29899a8a6df09cd7c5228bf8a0482)
BibTeX
@misc{dc489d49160e68,
  title = {Safety profile and efficacy of secukinumab in the treatment of autoimmune myasthenia gravis: a single-center retrospective study — Europe PMC PMID:41200446},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41200446},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_489d49160e68; sha256 9b03356b2030c7e68f4fe7f23de7b044b7c29899a8a6df09cd7c5228bf8a0482},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41200446. Agents can read the archived copy with the MCP tool read_document.